2m 2m 2m 2m 2m 2m 2m
Anika Therapeuti (ANIK)
NASDAQ
$14.39-$0.03 (-0.17%)
Price as of Jun 03, 2026 4:10 PM EDT- $193.3MMarket Cap
- 23.69%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Anika Therapeuti (ANIK)
$14.39-$0.03 (-0.17%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 112.8M -5.91% | 119.9M -28.05% | 166.7M +6.67% | 156.2M +5.71% | |
Cost of Revenue | 49.0M +11.62% | 43.9M -30.93% | 63.6M +1.46% | 62.7M -3.38% | |
Gross Profit | 63.8M -16.04% | 76.0M -26.28% | 103.1M +10.16% | 93.6M +12.82% | |
Sales and Marketing Expense | 49.1M -11.64% | 55.6M -42.04% | 95.8M +13.04% | 84.8M +14.44% | |
Research and Development Expense | -25.8M +0.88% | -25.5M -21.86% | -32.7M +16.00% | -28.2M +3.13% | |
Depreciation and Amortization Expense | 5.4M -21.96% | 6.9M +6.99% | 6.4M -4.03% | 6.7M +3.46% | |
Total Operating Expenses | 74.9M -7.70% | 81.1M -57.48% | 190.7M +68.82% | 113.0M +40.64% | |
Operating Profit | -11.1M +116.64% | -5.1M -94.18% | -87.6M +351.75% | -19.4M -841.87% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | 0 +100.00% | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 +100.00% | |
Total Nonoperating Income and Expense | 1.7M -25.37% | 2.3M +1.08% | 2.3M +253.52% | 654,000 +447.87% | |
Income before Taxes | -9.3M +236.72% | -2.8M -96.76% | -85.3M +355.17% | -18.7M -872.39% | |
Income Taxes | 672,000 -88.92% | 6.1M +327.97% | -2.7M -31.57% | -3.9M +127.71% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -10.9M -80.70% | -56.4M -31.79% | -82.7M +456.34% | -14.9M -459.43% | |
Net Income from Continuing Operations Applicable to Common | -10.0M +13.04% | -8.8M -89.65% | -85.3M +355.17% | -18.7M -872.39% | |
Basic EPS and Net Income | -0.76 -80.16% | -3.83 -32.09% | -5.64 +452.94% | -1.02 -451.72% | |
Diluted EPS and Net Income | -0.76 -80.16% | -3.83 -32.09% | -5.64 +452.94% | -1.02 -464.29% | |
Basic Weighted Average Shares | 14.3M -2.59% | 14.7M +0.44% | 14.7M +0.65% | 14.6M +1.11% | |
Diluted Weighted Average Shares | 14.3M -2.59% | 14.7M +0.44% | 14.7M +0.65% | 14.6M -0.50% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 57.5M +3.33% | 55.6M -23.66% | 72.9M -15.59% | 86.3M -8.54% | |
Short-Term Investments | 23.7M +0.41% | 23.6M -34.39% | 36.0M +3.85% | 34.6M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 81.2M +2.46% | 79.2M -27.20% | 108.8M -10.03% | 121.0M +28.15% | |
Total Current Assets | 103.4M -9.06% | 113.7M -30.41% | 163.3M -3.68% | 169.5M +0.60% | |
Accumulated Depreciation | 51.4M +11.11% | 46.3M -2.91% | 47.7M +3.22% | 46.2M +16.67% | |
Property and Plant and Equipment and Net | 40.3M +3.41% | 39.0M -15.59% | 46.2M -4.31% | 48.3M +1.42% | |
Total Long-Term Assets | 4.0M -28.68% | 5.7M -69.71% | 18.7M +8.44% | 17.2M -15.11% | |
Total Assets | 190.3M -6.15% | 202.7M -25.09% | 270.6M -22.48% | 349.1M +0.46% | |
Income Taxes Payable | 0 -100.00% | 63,000 N/A | 0 -100.00% | 6.4M -36.63% | |
Total Short-Term Debt | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Current Liabilities | 21.9M -6.00% | 23.3M -24.96% | 31.1M +11.27% | 27.9M -6.31% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 701,000 -9.20% | 772,000 +91.09% | 404,000 +1.51% | 398,000 -68.36% | |
Total Liabilities | 46.1M -2.57% | 47.3M -18.36% | 58.0M +2.17% | 56.7M +15.69% | |
Retained Earnings | 60.8M -15.18% | 71.7M -44.03% | 128.1M -39.23% | 210.7M -6.59% | |
Total Stockholders Equity | 143.5M -6.83% | 154.0M -27.45% | 212.3M -25.67% | 285.6M -0.53% | |
Total Shares Outstanding | 13.9M -3.66% | 14.4M -1.66% | 14.7M +0.24% | 14.6M +1.27% | |
Cash Flow | |||||
Cash from Operating Activities | 11.2M +107.07% | 5.4M +402.18% | -1.8M -140.55% | 4.4M -47.49% | |
Capital Expenditures | 6.8M -11.74% | 7.7M +42.51% | 5.4M -27.50% | 7.5M +45.56% | |
Cash from Investing Activities | -401,000 -95.19% | -8.3M +53.57% | -5.4M -27.50% | -7.5M +140.09% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -10.6M -17.11% | -12.7M +101.28% | -6.3M +30.34% | -4.9M -28.43% | |
Financials Ratio | |||||
Gross Margin | 56.56% -10.77% | 63.38% +2.47% | 61.85% +3.27% | 59.89% +6.72% | |
Operating Margin | -9.80% +130.26% | -4.25% -91.91% | -52.58% +323.49% | -12.42% -801.77% | |
Return on Assets | -5.54% -76.76% | -23.82% -10.70% | -26.68% +525.37% | -4.27% -467.93% | |
Return on Equity | -7.32% -76.24% | -30.79% -7.29% | -33.21% +539.95% | -5.19% -451.17% | |
Revenue Growth | -5.91% -78.93% | -28.05% -520.40% | 6.67% +16.83% | 5.71% -57.02% | |
Current Ratio | 4.72 -3.25% | 4.88 -7.26% | 5.26 -13.43% | 6.07 +7.38% | |
Cash Ratio | 2.62 +9.92% | 2.39 +1.74% | 2.35 -24.14% | 3.09 -2.37% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow